Detection and characterization of lung cancer using cell-free DNA fragmentomes
-
Published:2021-08-20
Issue:1
Volume:12
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Mathios Dimitrios, Johansen Jakob SideniusORCID, Cristiano Stephen, Medina Jamie E., Phallen JillianORCID, Larsen Klaus R., Bruhm Daniel C., Niknafs Noushin, Ferreira Leonardo, Adleff Vilmos, Chiao Jia Yuee, Leal AlessandroORCID, Noe Michael, White James R., Arun Adith S., Hruban Carolyn, Annapragada Akshaya V.ORCID, Jensen Sarah ØstrupORCID, Ørntoft Mai-Britt Worm, Madsen Anders Husted, Carvalho BeatrizORCID, de Wit Meike, Carey Jacob, Dracopoli Nicholas C., Maddala Tara, Fang Kenneth C., Hartman Anne-Renee, Forde Patrick M., Anagnostou ValsamoORCID, Brahmer Julie R., Fijneman Remond J. A.ORCID, Nielsen Hans Jørgen, Meijer Gerrit A., Andersen Claus LindbjergORCID, Mellemgaard Anders, Bojesen Stig E.ORCID, Scharpf Robert B.ORCID, Velculescu Victor E.ORCID
Abstract
AbstractNon-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for cancer detection and intervention. Here, we use a machine learning model for detecting tumor-derived cfDNA through genome-wide analyses of cfDNA fragmentation in a prospective study of 365 individuals at risk for lung cancer. We validate the cancer detection model using an independent cohort of 385 non-cancer individuals and 46 lung cancer patients. Combining fragmentation features, clinical risk factors, and CEA levels, followed by CT imaging, detected 94% of patients with cancer across stages and subtypes, including 91% of stage I/II and 96% of stage III/IV, at 80% specificity. Genome-wide fragmentation profiles across ~13,000 ASCL1 transcription factor binding sites distinguished individuals with small cell lung cancer from those with non-small cell lung cancer with high accuracy (AUC = 0.98). A higher fragmentation score represented an independent prognostic indicator of survival. This approach provides a facile avenue for non-invasive detection of lung cancer.
Funder
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation SU2C in-Time Lung Cancer Interception Dream Team Grant, Stand Up to Cancer-Dutch Cancer Society International Translational Cancer Research Dream Team Grant
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference62 articles.
1. Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941–1953 (2019). 2. De Angelis, R. et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol. 15, 23–34 (2014). 3. de Groot, P. M., Wu, C. C., Carter, B. W. & Munden, R. F. The epidemiology of lung cancer. Transl. Lung Cancer Res. 7, 220–233 (2018). 4. de Koning, H. J. et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N. Engl. J. Med. 382, 503–513 (2020). 5. National Lung Screening Trial Research, T. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409 (2011).
Cited by
228 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|